読み込み中
NASDAQHealthcareBiotechnology
最新データ
$1.91
+$0.04 · +2.14%
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
前日終値
$1.91
+$0.04 · +2.14%
日中の時刻はETです。市場データは遅延する場合があります。
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
日中レンジ
現在 $1.91
52週レンジ
現在 $1.91
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
31
割高
センチメント
48
まちまち
リスク
73
高リスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
日中レンジ
現在 $1.91
52週レンジ
現在 $1.91
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 135.6万 USD | 100.6万 USD | 53.6万 USD | — | — |
| 粗利益 | −135.6万 USD | −100.6万 USD | −53.6万 USD | — | — |
| 研究開発 | 5999万 USD | 6399.2万 USD | 4548.8万 USD | 2394.9万 USD | 1371.8万 USD |
| 販売・一般管理 | 2412.4万 USD | 2520.7万 USD | 2121.3万 USD | 870.8万 USD | 246.6万 USD |
| 営業費用 | 8275.8万 USD | 8819.3万 USD | 6670.1万 USD | 3265.7万 USD | 1618.4万 USD |
| 受取利息 | 647.9万 USD | 920.1万 USD | 703.7万 USD | — | — |
| 減価償却費と償却費 | 135.6万 USD | 100.6万 USD | 53.6万 USD | 36.4万 USD | 3.7万 USD |
| 営業利益 | −8411.4万 USD | −8919.9万 USD | −6723.7万 USD | −3265.7万 USD | −1618.4万 USD |
| 純利益 | −7790.5万 USD | −8055.6万 USD | −6038.8万 USD | −3116.7万 USD | −1624.3万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI114.02万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF81.42万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC11.6万0.01%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.09%1.17億 USD0.73%$15.9402+0.25%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.32万0.00%61.81億 USD0.26%$68.28+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Vector Equity Portfolio ETF Class SharesDXUVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
